Showing results (141-150 of 147) with videos related to
Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 147 results.
The New England Journal of Medicine|October 22, 2025
Nivolumab for Resected Stage III or IV Melanoma at 9 YearsPaolo A Ascierto, Michele Del Vecchio, Barbara Merelli, et al.Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.Signal Transduction and Targeted Therapy|June 16, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutationDan-Yun Ruan, Hao-Xiang Wu, Ye Xu, et al.JAMA Oncology|March 5, 2026
Genomic Therapy Matching in Rare and Refractory CancersFrank P Lin, Subotheni Thavaneswaran, John P Grady, et al.The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238James Larkin, Michele Del Vecchio, Mario Mandalá, et al.Journal for Immunotherapy of Cancer|April 23, 2020
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanomaJonathan S Cebon, Martin Gore, John F Thompson, et al.Pageof 15